000			01755 a2200493 4500
005			20250515160733.0
264		0	_c20091028
008			200910s 0 0 eng d
022			_a1440-1746
024	7		_a10.1111/j.1440-1746.2009.05786.x _2doi
040			_aNLM _beng _cNLM
100	1		_aTrinder, Matthew W
245	0	0	_aEfficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. _h[electronic resource]
260			_bJournal of gastroenterology and hepatology _cJul 2009
300			_a1252-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAnti-Inflammatory Agents _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAustralia
650	0	4	_aChild
650	0	4	_aColitis, Ulcerative _xdiagnosis
650	0	4	_aCrohn Disease _xdiagnosis
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aGastrointestinal Agents _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aInfliximab
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProspective Studies
650	0	4	_aRemission Induction
650	0	4	_aSeverity of Illness Index
650	0	4	_aTime Factors
650	0	4	_aTreatment Failure
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
650	0	4	_aYoung Adult
700	1		_aLawrance, Ian C
773	0		_tJournal of gastroenterology and hepatology _gvol. 24 _gno. 7 _gp. 1252-7
856	4	0	_uhttps://doi.org/10.1111/j.1440-1746.2009.05786.x _zAvailable from publisher's website
999			_c18663646 _d18663646